Zevra Therapeutics (ZVRA) Cash from Investing Activities Growth (1y) (2015 - 2026)
Powered by 
Analysis
Zevra Therapeutics (ZVRA) Cash from Investing Activities Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -41.67% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -157.08% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 26.37% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -89.24% |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn | 163.54% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 163.54% |
| Mar 31, 2026 | 655.25% |
| Dec 31, 2025 | 104.15% |
| Sep 30, 2025 | 85.41% |
| Jun 30, 2025 | 9,351.16% |
| Mar 31, 2025 | -28.74% |
| Dec 31, 2024 | -151.69% |
| Sep 30, 2024 | 29.47% |
| Jun 30, 2024 | -100.38% |
| Mar 31, 2024 | 184.27% |
| Dec 31, 2023 | 16,901.59% |
| Sep 30, 2023 | -16,444.12% |
| Jun 30, 2023 | 202.89% |
| Mar 31, 2023 | -356.21% |
| Dec 31, 2022 | 99.59% |
| Sep 30, 2022 | 6,900.00% |
| Jun 30, 2022 | -40,739.51% |
| Dec 31, 2021 | -59,280.77% |
| Jun 30, 2021 | -2,125.00% |
| Dec 31, 2020 | -420.00% |